| This week's sponsor is CMIC Group. | | | |
Today's Rundown Hatteras raises $94M to invest in early-stage biotechs Early Alzheimer's biotech, late-stage heart drug company gun for $86M IPOs Applied Therapeutics eyes $86M IPO to advance metabolic disease programs [Sponsored] Mitotech: a Dry Eye treatment aimed at mitochondria EIP bags cash to trial ex-Vertex drug in dementia, Huntington's Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135M Bringing CAR-T cancer treatments to solid tumors with help from alpacas Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices Featured Story | | | Monday, April 15, 2019 Hatteras Venture Partners has raised $94 million for its sixth venture fund. The first close of the targeted $200 million fund tees Hatteras up to make a fresh batch of seed and early-stage biotech investments. |
|
|
Top Stories Monday, April 15, 2019 Two very different biotechs—one focused on pushing through an early Alzheimer’s disease drug and the other a phase 3 heart rate condition company—are looking for the very same IPO price. Monday, April 15, 2019 The IPO will bankroll a trio of assets through the clinic, including two for complications of diabetes and one for galactosemia, a rare genetic disorder. Monday, April 15, 2019 Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease. Monday, April 15, 2019 EIP Pharma has raised $11.2 million to expand its clinical trial activities beyond Alzheimer's disease. The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease. Monday, April 15, 2019 Castle Creek will assume manufacturing and development costs for Fibrocell's gene therapy for recessive dystrophic epidermolysis bullosa until the duo files for FDA approval. Monday, April 15, 2019 Scientists at Boston Children's Hospital and MIT built CAR-T cells that are inspired by alpaca antibodies and can target protective proteins around solid tumors. They plan to test the approach in pancreatic and bile duct cancers. Monday, April 15, 2019 In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal. | This week's sponsor is Sensors Expo. | | | |
Resources Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 